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 INTRODUCTION 
One of the key challenges in oral drug delivery is to 
increase the dissolution rate and solubility of poorly
water-soluble drugs and thereby, improve the oral 
bioavailability of the drugs. One solution is to 
modify the actual drug formulation, but recently 
micro fabricated drug delivery devices have been 
proposed as alternative oral drug delivery systems 
[1,2]. Microcontainers are small polymeric devices 
consisting of a flat base with a walled reservoir and 
have been suggested as a potential approach to 
increase the oral drug bioavailability [3,4]. The 
microcontainers are characterised by enabling 
unidirectional release directly to the intestinal 
mucosa, as only one side of the microcontainers is 
open. The cavity of the microcontainers is filled with 
drug and subsequently coated with a lid of a pH-
sensitive polymer to protect the drug from 
degradation and premature release in the stomach. 
After emptying into the duodenum the polymer lid 
will dissolve at the higher pH in the small intestine 
and the drug is released and absorbed through the 
intestinal wall (Fig. 1). A challenge that has not been 
addressed so far is to fabricate the microcontainers 
using a biodegradable polymer. Here, we 
demonstrate the fabrication of the microcontainers 
with Poly-L-lactic acid (PLLA), a polymer approved 
by the US Food and Drug administration (FDA) for 
drug delivery purposes and categorised as a 
biopolymer with long biodegradation time [5] and 
therefore, suitable to use for fabrication of the 
microcontainers for oral drug delivery. 
The purpose was to fabricate microcontainers in 
PLLA polymer films using hot embossing, and to 
identify a method to fill powders into the 
microcontainers. Moreover, the application of 
fabricated microcontainers as an oral drug delivery 
system for a poorly soluble drug was studied (Fig. 
1). 
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Fig. 1. Illustrations of the experimental methods. A) 
Fabrication of PLLA microcontainers. B) Filling with 
amorphous furosemide salt. C) Spray coating of a lid of 
Eudragit L100. D) Dissolution of coating and release of 
drug. 
EXPERIMENTAL METHODS 
For fabrication of the PLLA microcontainers, a film 
of PLLA was deposited by spin coating on a silicon 
wafer. The film was heated above the glass transition 
temperature (Tg) of the polymer, and a Nickel stamp 
was pressed into the film. Following cooling of the 
film, the stamp was removed, exposing the formed 
microcontainers. The microcontainers were filled with 
amorphous furosemide sodium salt (produced by 
spray drying) [6] using a simplified version of a 
screen printing technique (Fig. 2).  
 
Fig. 2: Graphics showing the powder filling process of 
PLLA microcontainers using screen printing 
modifications. 1. The stencil was aligned to the 
microcontainers. 2-3. Furosemide was pressed into the 
microcontainers. 4. The stencil was removed resulting in 
filled PLLA microcontainers.  
 A gastric-resistant lid of Eudragit L100 was 
subsequently spray coated onto the cavity of the 
microcontainers. Release of amorphous furosemide 
salt from the coated microcontainers was 
investigated using a µ-Diss profiler (pIon Inc). 
Release experiments were carried out in biorelevant 
gastric medium (pH 1.6) for 2 h, followed by 3 h in a 
biorelevant intestinal medium (pH 6.5). Moreover, 
biorelevant flow through dissolution was also carried 
out in conjunction with UV imaging (Sirius
Analytical) to visualise the release of amorphous 
furosemide salt from the coated microcontainers. 
 
RESULTS AND DISCUSSION 
The Nickel stamp, utilised for the hot embossing 
process, made the fabrication of the microcontainers 
very robust, resulting in PLLA microcontainers with 
an inner diameter of 240 µm and a height of 100 µm 
(Fig 3).  
 
 
Fig. 3: SEM image of a single microcontainer in 
polylactic acid (PLLA) after hot embossing. Outer 
diameter of 300 µm, inner diameter of 240 µm, and 
height of 100 µm.  
 
The filling of amorphous furosemide salt into the 
microcontainers using the screen printing technique 
was shown to be a very useful method for quickly 
filling the microcontainers while avoiding deposition 
of drug powder in between the microcontainers (Fig 
4a). Moreover, the method can be utilised for all 
type of powders. The lid of Eudragit L100 on the 
microcontainers can be seen in Fig. 4b.  
 
a) b)
Fig. 4: a) An optical microscope image of a PLLA 
microcontainers filled with furosemide. b) A SEM 
image of drug-filled PLLA microcontainers spray 
coated with Eudragit L100. 
 
 
 
From both release experiments (in the µ-Diss profiler 
and UV imaging system) it was observed that the 
Eudragit layer prevented drug release in biorelevant 
gastric medium, while an immediate release of the 
amorphous furosemide salt was seen in the biorelevant 
intestinal medium (Fig. 5). 
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Fig 5: Release profiles obtained in µ-Diss profiler from
PLLA microcontainers filled with furosemide and coated 
with Eudragit L100 in gastric medium pH 1.6 (from 0-120 
min) and intestinal medium pH 6.5 (120-300 min). Data 
shown represent the mean of 3 replicates±SD.  
 
CONCLUSION 
Biodegradable microcontainers in PLLA were 
successfully fabricated and loaded with drug powder. 
Coating with Eudragit L100 proved to be useful for 
protecting drug release from microcontainers in gastric 
medium, and facilitated an immediate release in the 
intestinal medium. The fabricated microcontainers 
therefore show considerable potential as new 
 oral drug delivery systems. 
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